Sean Stalfort
Independent DirectorMr. Sean Stalfort is Director of Curadel Surgical Innovations, Inc. Mr. Stalfort has been an Independent Director of Acumen Pharmaceuticals, Inc. since October 2018 and served as its Independent Chairman of the Board. He serves as President at PBM Capital Group, LLC and served as its Principal since May 2010. He has been Independent Director of Taysha Gene Therapies, Inc. since June 21, 2023. Mr. Stalfort also serves on the board of directors of Baxis Pharmaceuticals, Inc. and Vetana Animal Health, Inc. He serves as Investment and Capital Market Advisor at Xalud Therapeutics, Inc. He has worked at PBM Capital since 2010. He focuses on sources and structures new investment opportunities, oversees many of the portfolio companies and serves on the Board of Directors for, Xalud Therapeutics, Tolerion Inc. and Quantapore, Inc. Mr. Stalfort serves as Director of SalioGen Therapeutics, Inc since September 01, 2021. Prior to joining PBM Capital Group, LLC, Mr. Stalfort served as the Executive Vice President of New Business Development/M&A at PBM Products. He was a Founding Partner at Benevolent Capital Partners. Prior to Benevolent Capital, Mr. Stalfort was a Co-founder and Principal of Octagon Partners LLC. Mr. Stalfort is also a Founding Partner of Octagon Partners and Octagon Finance, historic tax credit real estate companies. Prior to Octagon Partners, he was a Founding Partner at Ravelin Capital Group, LLC. Prior to that, Mr. Stalfort was a Managing Director and Founding Partner at Capital Solutions Group. Previously, he served as a Senior Vice President and Founding Principal at Enterprise Mortgage. Prior to that, Mr. Stalfort was a Vice President at Greenwich Capital’s Asset-Backed Finance Group, participating in various ABS, merchant banking and real estate transactions. He also worked with the trading desk to value a variety of esoteric mortgage backed securities. Mr. Stalfort also served as President of Dova Pharmaceuticals Inc. from April 2016 to December 2016. He served as a Director of Advantagene, Inc. He served as a Director of Dova Pharmaceuticals Inc. since September 2016 until November 12, 2019. He has been a Director of Verrica Pharmaceuticals Inc. since December 2015. He began his career as an Investment Banking Credit Analyst in Fixed Income Sales and Trading Group at CS First Boston in New York. He holds a B.A. in Business Economics and Political Science from the Brown University in 1991.
Positions
- Company NameTaysha Gene Therapies, Inc.Stock CodeTSHAPositionIndependent DirectorColleagues
- SPSean P. NolanCEO & Chairman
- SNSukumar NagendranPresident, Head of Research & Development and Director
- KAKamran AlamCFO & Corporate Secretary
- HCHayleigh CollinsDirector of Corporate Communications & Investor Relations
- MBMichael B. JohannesenChief Legal Officer & Corporate Secretary
- PBPhillip B. DonenbergIndependent Director
- LSLaura Sepp-LorenzinoIndependent Director
